News

Bausch Health’s OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease

Expansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL,…

2 months ago

TailorMed Showcases Innovative Patient-Facing Solution at Becker’s Fall Chief Pharmacy Officer Summit

TailorMed Connect Gives Patients Direct Access to Critical Support While Scaling Health Systems' Impact NEW YORK, NY / ACCESS Newswire…

2 months ago

Standard Dental Labs Signs Binding Agreement to Acquire Dream Dentistry Labs, LLC, Strengthening Central Florida Operations

ORLANDO, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” or the “Company”) today announced…

2 months ago

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30…

2 months ago

Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S. 

Harel Gadot, President and CEO, Microbot Medical Announces LIBERTY® Limited Market Release Company Completes the Required Infrastructure to Support the…

2 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline…

2 months ago

Normunity announces first patient dosed in Phase 1 clinical study of NRM-823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or…

2 months ago

YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring

Taipei, Taiwan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (NasdaqGM: YDES), a biotechnology…

2 months ago

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a…

2 months ago

Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

TORONTO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF)…

2 months ago